Literature DB >> 2043494

High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.

C Louvet1, A de Gramont, B Demuynck, B Nordlinger, J E Maisani, B Lagadec, S Delfau, C Varette, G Gonzalez-Canali, M Krulik.   

Abstract

Twenty-five patients with advanced measurable gastric cancer were treated with high-dose folinic acid (200 mg/m2), 5-fluorouracil bolus (400 mg/m2) and continuous infusion (600 mg/m2) for two consecutive days every two weeks. Fourteen patients over 65 yr old and/or with a poor general status received first-line treatment, and eleven younger patients second-line. The response rate was 43.5% in 23 evaluable patients. There were 2 complete responses (8.7%) and 8 partial responses (34.8%). Median survival was 6 months in first-line and 8 months, calculated from start of folinic acid-5FU, in second-line. Toxicity was mild without WHO Grade greater than 2 events. This combination is effective for advanced gastric cancer in poor-prognosis patients and requires further studies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043494     DOI: 10.1093/oxfordjournals.annonc.a057914

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

1.  Randomized phase III trial of cisplatin, epirubicin, leucovorin, 5-fluorouracil (PELF) combination versus 5-fluorouracil alone as adjuvant chemotherapy in curative resected stage III gastric cancer.

Authors:  Jae Jin Lee; Si-Young Kim; Im Sik Shin; Kyung Sam Cho; Hoong-Zae Joo; Choong Yoon; Yoon Wha Kim; Hwi Joong Yoon
Journal:  Cancer Res Treat       Date:  2004-04-30       Impact factor: 4.679

2.  Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.

Authors:  André M Murad; Nils G Skare; Jéferson Vinholes; Sérgio Lago; Ricardo Pecego
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

3.  Chemotherapy for advanced gastric cancer: slow but further progress.

Authors:  Yeul Hong Kim
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

4.  Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study.

Authors:  Pavlos Papakostas; Dimitrios Tsavdaridis; Paris Kosmidis; Haralabos P Kalofonos; Athanassios Sakantamis; Dimitrios Janinis; Dimosthenis Skarlos; Dimitrios Bafaloukos; Aristotelis Bamias; Nikos Xiros; George Fountzilas
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

5.  Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.

Authors:  Ilkay Tugba Unek; Tulay Akman; Ilhan Oztop; Olcun Umit Unal; Tarik Salman; Ugur Yilmaz
Journal:  Gastric Cancer       Date:  2012-10-22       Impact factor: 7.370

6.  Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.

Authors:  M González-Barón; J Feliu; E Espinosa; C García-Girón; I Chacón; P Garrido; A Colmenarejo; A Ordóñez; P Zamora
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.

Authors:  M S Highley; M E Hill; N Ziras; N Samandas; R C Mason; W Owen; J Dussek; S Barker; P G Harper
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

8.  Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Authors:  Y Chao; K H Yeh; C J Chang; L T Chen; T Y Chao; M F Wu; C S Chang; J Y Chang; C Y Chung; W Y Kao; R K Hsieh; A L Cheng
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

9.  Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer.

Authors:  T Conroy; F Viret; E François; J F Seitz; V Boige; M Ducreux; M Ychou; J P Metges; M Giovannini; Y Yataghene; D Peiffert
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.